{
    "Allocation": "Randomized",
    "CompleteTime": 180,
    "DesignModel": "Parallel Assignment",
    "DrugInformation": {
        "ArmGroupList": [
            {
                "ArmGroupDescription": "arsenic trioxide: 0.15 mg/Kg 4 weeks(twice daily) , all-trans retinoic acid (atra): 10 mg 2 weeks , ",
                "ArmGroupLabel": "ARM A - ATO/ATRA",
                "ArmGroupType": "Experimental",
                "InterventionDescription": [
                    {
                        "Dosage": "0.15 mg/Kg",
                        "DrugName": "arsenic trioxide",
                        "Duration": "4 weeks(twice daily)",
                        "HowToTake": ""
                    },
                    {
                        "Dosage": "10 mg",
                        "DrugName": "all-trans retinoic acid (atra)",
                        "Duration": "2 weeks",
                        "HowToTake": ""
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "Drug: arsenic trioxide",
                        "Drug: all-trans retinoic acid (ATRA)"
                    ]
                }
            },
            {
                "ArmGroupDescription": "idarubicin: 12 mg/m2 days 1(3rd cycle) infusion, mercaptopurine: 50 mg/m2 50 mg/m2/day(once daily)(every 3 months) orally, methotrexate: 15 mg/m2 weekly(once weekly)(every 3 months)(once daily) intramuscularly, all-trans retinoic acid: 45 mg/m2/day two year , ",
                "ArmGroupLabel": "ARM B - ATRA",
                "ArmGroupType": "Active Comparator",
                "InterventionDescription": [
                    {
                        "Dosage": "12 mg/m2",
                        "DrugName": "idarubicin",
                        "Duration": "days 1(3rd cycle)",
                        "HowToTake": "infusion"
                    },
                    {
                        "Dosage": "50 mg/m2",
                        "DrugName": "mercaptopurine",
                        "Duration": "50 mg/m2/day(once daily)(every 3 months)",
                        "HowToTake": "orally"
                    },
                    {
                        "Dosage": "15 mg/m2",
                        "DrugName": "methotrexate",
                        "Duration": "weekly(once weekly)(every 3 months)(once daily)",
                        "HowToTake": "intramuscularly"
                    },
                    {
                        "Dosage": "45 mg/m2/day",
                        "DrugName": "all-trans retinoic acid",
                        "Duration": "two year",
                        "HowToTake": ""
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "Drug: idarubicin",
                        "Drug: mercaptopurine",
                        "Drug: methotrexate",
                        "Drug: all-trans retinoic acid"
                    ]
                }
            }
        ]
    },
    "Enrollment": "276",
    "InterventionName": "methotrexate",
    "Masking": "None (Open Label)",
    "NCTID": "NCT00482833",
    "Objective": "Phase III Trial in Acute Promyelocytic Leukemia Patients",
    "OfficialTitle": "A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia",
    "PopulationBox": {
        "Condition": "Leukemia",
        "Gender": "All",
        "HealthyCondition": "No",
        "MaxAge": "70 Years",
        "MinAge": "18 Years",
        "Participant": "276"
    },
    "PopulationRatio": "",
    "Title": "Phase III Trial in Acute Promyelocytic Leukemia Patients",
    "WashoutPeriod": ""
}